First transdermal oxycodone nears Phase III as Phosphagenics cues up next opioid target
This article was originally published in Scrip
With formulation issues for its lead therapeutic product now resolved, Phosphagenics looks set to apply for the approval of a pivotal clinical program for its first-in-class transdermal oxycodone product well within the first half of next year.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.